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granulocyte–macrophage (GM) colony-stimulating factor 
(9). Although these autoantibodies have not been reported 
in patients with Listeria infections, susceptibility to infec-
tion caused by this bacterium is increased in GM–colony-
stimulating factor –/– mice (10). Autoantibodies against 
GM–colony-stimulating factor or perhaps other cytokines 
might have impaired the patient’s host defense against 
these organisms; unfortunately, our report is limited by lack 
of serum for further testing.
This case demonstrates the difficulties of managing 
patients with C. gattii infection and an unusual co-infec-
tion with L. monocytogenes. Initiation of corticosteroids 
for the management of severe cryptococcal disease should 
be undertaken with caution. The differential diagnosis for 
worsening cryptococcal disease should include acute or 
subacute bacterial meningitis, particularly when the pa-
tient is receiving corticosteroids for the management of 
immune reconstitution inflammatory syndrome or associ-
ated complications.
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To the Editor: Melioidosis, a potentially fatal infec-
tious disease, occurs predominantly across much of Asia 
and in northern Australia because of the soil and water bac-
terium Burkholderia pseudomallei (1). We report 2 related 
cases of suppurative cervical lymphadenitis, an unusual 
adult presentation of melioidosis, in 2 men who returned to 
France from Vietnam on the same trip (2).
Patient 1, a 28-year-old previously healthy man, was 
admitted to our hospital in Lyon, France, in October 2013 
for the evaluation of a palpable neck mass, which had been 
growing steadily for the previous 2 months. Examination of 
the head and neck revealed a fluctuant, tender mass located 
in the inferior angle of the right side of the mandible, mim-
icking lymph node tuberculosis. Ultrasonographic investi-
gation confirmed a level II enlarged cervical lymph node 
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that was 2.8 cm in diameter. The routine bacterial culture 
from an ultrasound-guided fine needle aspiration showed 
a microorganism that was identified as B. pseudomallei by 
matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry analysis with an extended database. An 
investigation by local medical staff revealed that the symp-
toms of our patient began in August 2013, when he returned 
to France after attending a wedding ceremony in Vietnam, 
a country to which B. pseudomallei is known to be endemic 
(3). No environmental risk factors, such as the percutane-
ous inoculation of contaminated material, ingestion, or 
inhalation, which are the main routes of transmission of 
melioidosis, were reported (1). The interview of patient 1 
identified a co-traveler with similar symptoms (patient 2), 
who was subsequently admitted to the same hospital. 
Patient 2, a 31-year-old previously healthy man, re-
ported a 2-month history of a painful, inflamed, gradually 
enlarging, right-sided neck mass, accompanied by weight 
loss, night sweats, and intermittent fevers. Examination 
showed an enlarged cervical lymph node that was con-
firmed as level III, 3 cm in diameter. After noncontribu-
tory culture results from an ultrasound-guided fine needle 
aspiration, we performed an open biopsy under general 
anesthesia. We excised an adherent, enlarged, pus-filled 
lymph node and necrotic tissue for microbiologic testing. 
A real-time PCR assay specifically targeting type-3 secre-
tion system genes (orf11 and BpSCU2) quickly revealed 
the presence of B. pseudomallei DNA, and the diagnosis of 
melioidosis was confirmed by culture, matrix-assisted la-
ser desorption/ionization time-of-flight mass spectrometry, 
and antibiogram (4). 
For both patients, a cervical, chest, abdominal, and 
pelvic computed tomographic scan showed no other foci of 
infection, and a 14-day regimen of intravenous ceftazidime 
therapy was administered, followed by oral treatment with 
cotrimoxazole for 6 months (5). However, the neck mass 
of patient 1 was still swollen after 1 month of treatment, 
and oral amoxicillin/clavulanic acid was added to cotri-
moxazole for 2 months based on an antibiogram from a 
new bacterial isolation. For patient 2, cotrimoxazole was 
switched to amoxicillin/clavulanic acid after a presumed 
adverse drug reaction. At last report, both patients had been 
disease free for 20 months.
As soon as the second case of melioidosis was con-
firmed, local and national public health authorities in 
France were notified, and a larger contact investigation was 
initiated because 16 other travelers attended the same wed-
ding ceremony before returning to their home countries. 
None of these travelers had any symptoms of melioidosis. 
No serologic testing was performed. 
Although sporadic cases of travel-associated melioido-
sis are regularly reported, such case clusters occurring in 
returning travelers is rare but underscores the role of the 
contact investigation in this context (6–8). Phylogenetic 
analyses, performed by a 7-locus multilocus sequence typ-
ing analysis, revealed that the 2 isolates shared the same se-
quence type (381) (identification nos. 4488 and 4489, http://
pubmlst.org/bpseudomallei), which was previously identi-
fied in Thailand and Cambodia (9), suggesting a clonal in-
fection from a single-point source. The epidemiologic as-
sessment will be completed by whole-genome sequencing. 
Most cases of oropharyngeal melioidosis have been re-
ported in children and were believed to be associated with 
an oral contamination (1,3). The ingestion of unchlorinated 
or inefficiently chlorinated water from local residences 
and hotels has been involved in melioidosis outbreaks and 
could have been the route of infection for these patients. 
However, the source of infection might also be linked to a 
scooter ride taken by both men together around a lake in the 
vicinity of Hanoi (10). 
These patients had no known individual risk factor 
for melioidosis, such as diabetes, hazardous alcohol use, 
chronic lung or renal disease, thalassemia, glucocorticoid 
and other immunosuppressive therapy, or cancer, whereas 
up to 70% of patients with travel-associated melioidosis 
had >1 predisposing factor (1,8). However, the percentage 
of patients with an underlying risk factor dropped to 37.5% 
when the data excluded patients who were born in melioi-
dosis-endemic countries or others who had a long-term stay 
in a melioidosis-endemic country (6). This finding makes 
us cautious not to repeat making the common assumption 
about the link between underlying conditions and the risk 
for melioidosis, especially in regard to conventional tour-
ists traveling in melioidosis-endemic areas.
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To the Editor: A 61-year-old man underwent trans-
urethral prostate resection in Vancouver, British Columbia, 
in January 2016. On postoperative day 1, he was febrile 
(39.1°C) and had leukocytosis (12.7 × 109 cells/L). Blood 
and urine cultures were ordered on postoperative day 2, and 
ceftriaxone was started. On postoperative day 3, urine culture 
grew Escherichia coli (>100 million CFU/L). Susceptibility 
testing (VITEK2, bioMérieux, Quebec, Canada) indicated 
a possible extended-spectrum β-lactamase producer and 
showed resistance to ampicillin, cefazolin, ceftriaxone, gen-
tamicin, ciprofloxacin, and trimethoprim/sulfamethoxazole; 
intermediate resistance to tobramycin; and susceptibility to 
amoxicillin/clavulanate, piperacillin/tazobactam, ertapenem, 
meropenem, and nitrofurantoin. Treatment was switched to 
amoxicillin/clavulanate. The urinary catheter was removed 
48 hours later. The patient was discharged on postoperative 
day 5 and completed 14 days of oral amoxicillin/clavulanate. 
Blood cultures were negative after 7 days’ incubation.
The E. coli cultured from the patient underwent further 
testing and grew in equal amounts on Columbia Colistin-
Nalidixic acid Agar (CNA) with 5% sheep blood and Co-
lumbia agar with 5% sheep blood (OXOID, Ontario, Cana-
da). This result was brought to the attention of the hospital’s 
medical microbiologist. A colistin Etest (bioMérieux, Que-
bec, Canada) showed a MIC of 3 µg/mL; EUCAST defines 
colistin resistance as >2 µg/mL for Enterobacteriaceae (1).
A real-time PCR to detect the mobile colistin resis-
tance (mcr-1) gene was developed at the Provincial Public 
Health Laboratory by using primers MCR-1F (5′-CATC-
GCTCAAAGTATCCAGTGG-3′), MCR-1R (5′-CCATG-
TAGATAGACACCGTTCTCAC-3′), and probe MCR-1P 
(5′-Cy5-TGCAGACGCACAGCAATGCCTATGAT-
TAO-3′) with TaqMan Fast Advanced Master Mix (Life Tech-
nologies, Burlington, Ontario, Canada), on an ABI 7500 FAST 
thermocycler (Applied Biosystems, Foster City, CA) by using 
manufacturer’s’ recommended conditions. The mcr-1 gene 
was confirmed by Sanger sequencing by using previously de-
scribed oligonucleotides (2). The isolate was also PCR-positive 
for a blaCTX-M gene. The strain was sequenced by using MiSeq 
(Illumina, Victoria, British Columbia, Canada), and predicted 
to be sequence type 3944 based on multilocus sequence typ-
ing databases (http://github.com/tseemann/mlst; http://mlst.
warwick.ac.uk/mlst/dbs/Ecoli) and serotype O159:H4 (3). 
Sequence type 3944 does not belong to any clonal groups; 1 
isolate from Asia is in the MLST database. Abricate (http://
github.com/tseemann/abricate) and PlasmidFinder (4) were 
used to query the SPAdes-assembled genome (5). Results 
showed that this isolate carries 3 plasmids that have IncR, In-
cFIA/HI, and IncI2 replicons. The mcr-1 gene was found on a 
60,599-nt contig with the IncI2 replicon; this contig is ≈87% 
identical to pHNSHP45 (Figure) (2). The blaCTX-M-27 gene was 
found on the same contig as the IncFIA/HI replicon, and no 
resistance genes were found with the IncR replicon.
At the time of mcr-1 detection, the patient and all oth-
er patients who shared a hospital room with this patient, 
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